Header Logo

ANDRAS HECZEY

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard

    Collapse Biography 
    Collapse awards and honors
    2015Fellows' Excellence in Education Award, Texas Children's Cancer and Hematology Centers
    2012TXCH Tumor Board Award, Baylor College of Medicine
    2009Pediatric Associates and Affiliates Award, Children's Hospital of Los Angeles
    2000Good Student and Good Athlete of the Republic of Hungary , Ministry of Education of Hungary
    2020Young Investigator Award, Baylor College of Medicine

    Collapse Overview 
    Collapse overview
    Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).

    His research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack cancer cells.

    Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma, he is working on moving this approach from bench-to-bedside in a form of a Phase 1/2a clinical trial.

    As the Director of the Liver Tumor Program of Texas Children's Hospital, Dr. Heczey has developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically engineered T lymphocytes and he is currently evaluating this strategy in early Phase clinical trials in children and adults.

    Dr. Heczey is a member of the Liver Tumor Program, the Neuroblastoma Program, the Solid Tumor Team and the Center for Advanced Innate Cell Therapy.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Espinoza AF, Patel RH, Patel KR, Badachhape AA, Whitlock R, Srivastava RK, Govindu SR, Duong A, Kona A, Kureti P, Armbruster B, Kats D, Srinivasan RR, Dobrolecki LE, Yu X, Najaf Panah MJ, Zorman B, Sarabia SF, Urbicain M, Major A, Bissig KD, Keller C, Lewis MT, Heczey A, Sumazin P, L?pez-Terrada DH, Woodfield SE, Vasudevan SA. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 Apr; 80(4):610-621. PMID: 38242326.
      Citations:    Fields:    Translation:HumansAnimals
    2. Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2024 Jan 09. PMID: 38195754.
      Citations:    Fields:    
    3. Arnett AB, Heczey A. GD2-CAR CAR T?cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter. Cancer Cell. 2024 01 08; 42(1):8-10. PMID: 38134937.
      Citations:    Fields:    Translation:HumansCells
    4. Espinoza AF, Patel KR, Shetty PB, Whitlock RS, Sumazin P, Yu X, Sarabia SF, Urbicain M, Heczey A, Masand P, Woodfield SE, L?pez-Terrada DH, Vasudevan SA. Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy. Cancer Med. 2023 12; 12(23):21270-21278. PMID: 37962078; PMCID: PMC10726870.
      Citations: 1     Fields:    Translation:Humans
    5. Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388. PMID: 37188782.
      Citations: 4     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    6. Whitlock RS, Portuondo JI, Espinoza AF, Ortega R, Galv?n NTN, Leung DH, Lopez-Terrada D, Masand P, Nguyen HN, Patel KA, Goss JA, Heczey AM, Vasudevan SA. Surgical Management and Outcomes of Patients with Multifocal Hepatoblastoma. J Pediatr Surg. 2023 Sep; 58(9):1715-1726. PMID: 37244849.
      Citations:    Fields:    Translation:Humans
    7. Patra T, Cunningham DM, Meyer K, Toth K, Ray RB, Heczey A, Ray R. Targeting Lin28 axis enhances glypican-3-CAR T?cell efficacy against hepatic tumor initiating cell population. Mol Ther. 2023 03 01; 31(3):715-728. PMID: 36609146; PMCID: PMC10014222.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    8. Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24. PMID: 35325065; PMCID: PMC9346960.
      Citations:    Fields:    Translation:HumansCells
    9. Kahla JA, Siegel DA, Dai S, Lupo PJ, Foster JH, Scheurer ME, Heczey AA. Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. Pediatr Blood Cancer. 2022 10; 69(10):e29763. PMID: 35591805; PMCID: PMC9658228.
      Citations:    Fields:    
    10. Sumazin P, Peters TL, Sarabia SF, Kim HR, Urbicain M, Hollingsworth EF, Alvarez KR, Perez CR, Najaf Panah MJ, Epps JL, Scorsone K, Zorman B, Katzenstein H, O'Neill AF, Meyers R, Tiao G, Geller J, Ranganathan S, Rangaswami AA, Woodfield SE, Goss JA, Vasudevan SA, Heczey A, Roy A, Fisher KE, Patel KR, Finegold MJ, Pozza A, Alaggio R, L?pez-Terrada DH. Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022 10; 77(4):1026-1037. PMID: 35577029; PMCID: PMC9524481.
      Citations:    Fields:    
    11. Whitlock RS, Loo C, Patel K, Bista R, Goss JA, Heczey A, Khan O, Lopez-Terrada D, Masand P, Nguyen H, Mahvash A, Vasudevan SA, Kukreja K. Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma. J Pediatr Hematol Oncol. 2021 Nov 01; 43(8):e1181-e1185. PMID: 33769387.
      Citations:    Fields:    Translation:Humans
    12. Whitlock RS, Portuondo JI, Commander SJ, Ha TA, Zhu H, Goss JA, Kukreja KU, Leung DH, Terrada DL, Masand PM, Nguyen HN, Nuchtern JG, Wesson DE, Heczey AA, Vasudevan SA. Integration of a dedicated management protocol in the care of pediatric liver cancer: From specialized providers to complication reduction. J Pediatr Surg. 2022 Aug; 57(8):1544-1553. PMID: 34366130.
      Citations:    Fields:    Translation:Humans
    13. Goss MB, Munoz FM, Ruan W, O'Mahony CA, Rana A, Cotton RT, Moreno NF, Heczey AA, Leung DH, Goss JA, Galv?n NTN. Liver transplant in a recently COVID-19 positive child with hepatoblastoma. Pediatr Transplant. 2021 08; 25(5):e13880. PMID: 32979013; PMCID: PMC7536987.
      Citations: 6     Fields:    Translation:Humans
    14. Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690. PMID: 33046868.
      Citations: 57     Fields:    Translation:HumansCellsCTClinical Trials
    15. Whittle SB, Smith V, Silverstein A, Parmeter M, Minard CG, Bernhardt MB, Zage PE, Venkatramani R, Nuchtern JG, Heczey A, Russell HV, Shohet JM, Foster JH. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417. PMID: 32729196; PMCID: PMC7722106.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    16. Tay SY, Foster J, Heczey A, Sitton M. Pediatric Oncology Patients With Vincristine-Induced Recurrent Laryngeal Nerve Palsy: Two Case Reports and a Brief Review of Literature. Ear Nose Throat J. 2021 Dec; 100(10):NP459-NP463. PMID: 32425060.
      Citations: 1     Fields:    Translation:Humans
    17. Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS, Heczey A. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320. PMID: 31953246; PMCID: PMC10765595.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    18. Luckie TM, Potter SL, Bacino CA, Shah R, Heczey A, Venkatramani R. Agenesis of the corpus callosum and hepatoblastoma. Am J Med Genet A. 2020 01; 182(1):224-228. PMID: 31729153.
      Citations:    Fields:    Translation:Humans
    19. Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, Savoldo B, Dotti G, Metelitsa LS. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138. PMID: 31484667; PMCID: PMC6891170.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    20. Heczey A. Alliance of the Titans: An Effective Combination of a TKI with CAR T Cells. Mol Ther. 2019 08 07; 27(8):1348-1349. PMID: 31337604; PMCID: PMC6698246.
      Citations: 1     Fields:    Translation:AnimalsCells
    21. Cowell E, Patel K, Heczey A, Finegold M, Venkatramani R, Wu H, Miloh T, L?pez-Terrada D. Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. J Pediatr Gastroenterol Nutr. 2019 05; 68(5):695-699. PMID: 30676520.
      Citations: 3     Fields:    Translation:Humans
    22. Haines K, Sarabia SF, Alvarez KR, Tomlinson G, Vasudevan SA, Heczey AA, Roy A, Finegold MJ, Parsons DW, Plon SE, L?pez-Terrada D. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. Pediatr Blood Cancer. 2019 07; 66(7):e27745. PMID: 30977242.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    23. Rios X, Heczey AA. 50 Years Ago in The Journal of Pediatrics: Survival of Children with Neuroblastoma Treated with Combination Chemotherapy. J Pediatr. 2018 12; 203:233. PMID: 30470379.
      Citations:    Fields:    Translation:Humans
    24. Bavle A, Grimes A, Zhao S, Zinn D, Jackson A, Patel B, Porea T, Dutta A, Russell H, Heczey A. Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia. J Pediatr Hematol Oncol. 2018 10; 40(7):e415-e420. PMID: 29334532.
      Citations:    Fields:    Translation:Humans
    25. Ng K, Rana A, Masand P, Patel K, Heczey A, Goss J, Himes R. Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. J Pediatr Gastroenterol Nutr. 2018 01; 66(1):e21-e23. PMID: 28837514.
      Citations:    Fields:    Translation:Humans
    26. Newsome JR, Venkatramani R, Heczey A, Danysh HE, Fishman DS, Miloh T. Cholangiocarcinoma Among Children and Adolescents: A Review of the Literature and Surveillance, Epidemiology, and End Results Program Database Analysis. J Pediatr Gastroenterol Nutr. 2018 01; 66(1):e12-e18. PMID: 28937543.
      Citations: 3     Fields:    Translation:Humans
    27. Punia JN, Gaikwad A, Hampton OA, Heczey A, Whittle SB, L?pez-Terrada D. Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2017 11; 39(8):e486-e488. PMID: 28902076.
      Citations:    Fields:    Translation:HumansCells
    28. Hamilton EC, Balogh J, Nguyen DT, Graviss EA, Heczey AA, Austin MT. Liver transplantation for primary hepatic malignancies of childhood: The UNOS experience. J Pediatr Surg. 2017 Oct 12. PMID: 29108844.
      Citations: 3     Fields:    
    29. Szoor A, Vaidya A, Velasquez MP, Mei Z, Galvan DL, Torres D, Gee A, Heczey A, Gottschalk S. T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Mol Ther Oncolytics. 2017 Sep 15; 6:69-79. PMID: 28856237; PMCID: PMC5562179.
      Citations: 10     
    30. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224. PMID: 28602436; PMCID: PMC5589058.
      Citations: 168     Fields:    Translation:HumansCells
    31. Shi Y, Commander SJ, Masand PM, Heczey A, Goss JA, Vasudevan SA. Vascular invasion is a prognostic indicator in hepatoblastoma. J Pediatr Surg. 2017 Jun; 52(6):956-961. PMID: 28347528.
      Citations: 7     Fields:    Translation:Humans
    32. Heczey A, Fleurence J, Fougeray S, Bahri M, Cochonneau D, Cl?menceau B, Paris F, Birkl? S. Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. J Immunol Res. 2017; 2017:5604891. PMID: 28154831; PMCID: PMC5244029.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    33. Sumazin P, Chen Y, Sarabia SF, Hampton OA, Patel K, Mistretta TA, Zorman B, Thompson P, Heczey A, Comerford S, Wheeler DA, Chintagumpala M, Meyers R, Rakheja D, Finegold MJ, Tomlinson G, Parsons DW, Trevi?o LR, L?pez-Terrada D. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology. 2017 01; 65(1):104-121. PMID: 27775819.
      Citations: 59     Fields:    Translation:Humans
    34. Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther. 2017 05; 28(5):437-448. PMID: 27530312; PMCID: PMC5444493.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    35. Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, Guo L, Xu X, Torikai H, Mo Q, Dotti G, Cooper LJ, Metelitsa LS. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55. PMID: 27183388; PMCID: PMC4887157.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    36. Masand PM, Himes RW, Abbas R, Goss JA, Vasudevan SA, Finegold MJ, Heczey A, Techavichit P. Undifferentiated Embryonal Sarcoma of the Liver (UESL): A Single-Center Experience and Review of the Literature. J Pediatr Hematol Oncol. 2016 05; 38(4):261-8. PMID: 26925712.
      Citations: 23     Fields:    Translation:Humans
    37. Heczey A, Louis C. IMAGES IN CLINICAL MEDICINE. Osteopetrosis and Erlenmeyer-Flask Deformity. N Engl J Med. 2015 Sep 03; 373(10):e12. PMID: 26332566; PMCID: PMC4852467.
      Citations: 1     Fields:    Translation:Humans
    38. Austin MT, Nguyen H, Eberth JM, Chang Y, Heczey A, Hughes DP, Lally KP, Elting LS. Health disparities are important determinants of outcome for children with solid tumor malignancies. J Pediatr Surg. 2015 Jan; 50(1):161-6. PMID: 25598116; PMCID: PMC4408987.
      Citations: 13     Fields:    Translation:Humans
    39. Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, Liu H, Dotti G, Metelitsa LS. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014 Oct 30; 124(18):2824-33. PMID: 25049283; PMCID: PMC4215313.
      Citations: 113     Fields:    Translation:HumansAnimalsCells
    40. Heczey A, Louis CU. Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med. 2013 Dec; 16(90):287-94. PMID: 24333408; PMCID: PMC4106238.
      Citations: 18     Fields:    Translation:Humans
    41. Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, Dotti G, Metelitsa LS, Liu D. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33. PMID: 22565311; PMCID: PMC3366399.
      Citations: 67     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    HECZEY's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (200)
    Explore
    _
    Co-Authors (76)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _